Skip to search formSkip to main contentSkip to account menu

Refractory anaemia with excess blasts

Known as: Leukemias, Smoldering, Refractory Anemia with Excess Blasts, Smoldering Leukemia 
A myelodysplastic syndrome characterized by the presence of 5-19% myeloblasts in the bone marrow or 2-19% blasts in the peripheral blood. It includes… 
National Institutes of Health

Related topics

Related topics

25 relations
AgranulocytosisAnemiaBone MarrowBone marrow stem cell

Narrower (2)

RAEB-1RAEB-2

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
A review of the acculturation experiences of international students
Highly Cited
2011
Highly Cited
2011
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Prognostic factors for response and survival in higher-risk myelodysplastic syndrome patients treated with azacitidine (AZA… 
Highly Cited
2009
Highly Cited
2009
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before… 
Review
2003
Review
2003
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
Myelodysplastic and myeloproliferative disorders are rare in childhood and there is no widely accepted system for their diagnosis… 
Highly Cited
2001
Highly Cited
2001
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.
Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide with biologic effects that include regulation of… 
Highly Cited
2000
Highly Cited
2000
The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
Bone marrow CD34(+) cell apoptosis (annexin V), proliferation (Ki-67), and Bcl-2-related protein expression was evaluated by flow… 
Highly Cited
1999
Highly Cited
1999
Angiogenesis in myelodysplastic syndromes
It is now well established that solid tumour growth depends on angiogenesis. However, less is known about the generation of new… 
Highly Cited
1998
Highly Cited
1998
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
Treatment with erythropoietin (epo) may improve the anemia of myelodysplastic syndromes (MDS) in approximately 20% of patients… 
Highly Cited
1987
Highly Cited
1987
Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
The myelodysplastic syndromes are characterized by ineffective hematopoiesis and refractory cytopenias. In an attempt to improve… 
Highly Cited
1982
Highly Cited
1982
Proposals for the classification of the myelodysplastic syndromes
Summary. New, diagnostic criteria for the diagnosis of the various myelodysplastic syndromes (MDS) are proposed, and a detailed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)